Cellular Technology Limited

Executive Summary

Cellular Technology Limited (CTL) is a privately-held biotechnology company that has been a leader in immune monitoring for over 25 years, specializing in ELISPOT and FluoroSpot assay platforms. The company provides a comprehensive portfolio of analyzers, test kits, software, and contract research services, primarily serving immunology, vaccine development, and infectious disease research. CTL's proprietary platforms enable the detection and analysis of single immune cells secreting specific proteins, such as cytokines or antibodies, making their technology critical for preclinical and clinical research. With strong brand recognition in the immunology field and a focus on high-quality assay solutions, CTL is well-positioned to benefit from the growing demand for advanced immune monitoring tools, particularly as vaccine and immunotherapy development accelerates globally. Despite being private, the company holds a niche leadership position and has potential for expansion into new applications or geographic markets.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation FluoroSpot Assay Platform80% success
• 2026Strategic Partnership with Major Pharma for Vaccine Development60% success
• TBDExpansion into Point-of-Care or Companion Diagnostics Market40% success